COMMITMENTS AND CONTINGENCIES (Details) - USD ($)	12 Months Ended
	May 31, 2017	May 31, 2016
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement Term Period	10 years
Operating Lease Frequency of Periodic Payment	monthly
Operating Leases, Rent Expense	$ 2,926
Specimen Collection Study For H.pylori Testing [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Estimated Budget	85,000
Royalty Agreements [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Expense	$ 19,000	$ 24,000
Royalty Expense Percentage Of Sales	2.50%	3.50%
Exclusive Marketing License Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement Term Period	5 years
Additional Agreement Term Period	2 years
Operating Lease Rental [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Lease Initiation Date	Sep. 01, 2009
Lease Expiration Date	Aug. 31, 2016
Security Deposit Liability	$ 22,080
Operating Lease Rental [Member] | First Amendment To Lease [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Lease Expiration Date	Aug. 31, 2021
Operating Lease Rental [Member] | UNITED STATES
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense	$ 260,393	$ 235,927
Operating Lease Rental [Member] | MEXICO
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense	44,986	$ 36,234
Operating Lease Rental [Member] | Minimum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	21,000
Operating Lease Rental [Member] | Maximum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense, Minimum Rentals	23,637
US FDA [Member] | Exclusive Marketing License Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Clearance Fees	1,250,000
Conversion of Stock, Amount Converted	$ 250,000
Shares Issued, Price Per Share (in Dollars per share)	$ 3.00
Conversion of Stock, Shares Issued (in Shares)	83,333
Korean FDA [Member] | Exclusive Marketing License Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Agreement Term Period	5 years
Royalty Expense	$ 7,250,000
Celtis Pharm Co., Ltd [Member] | Private Placement [Member] | Exclusive Marketing License Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)	$ 3.00
Stock Issued During Period, Shares, New Issues (in Shares)	333,334
Stock Issued During Period, Value, New Issues	$ 1,000,002